Archive: February 25 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Acti...
Cord blood–derived natural killer (NK) immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant (ASCT), showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma (NHL), according to data from a phase 2 trial (NCT03019640) presented in a poster during the 2021 Transplant & Cellular Therapy Meetings.
Tisagenlecleucel Leads to High CR Rate in Heavily Pretreated, R/R Follicular Lym...
Tisagenlecleucel induced a significant number of complete responses in patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the phase 2 ELARA trial as of the interim analysis of the study.
Trispecific antibody targets cancer cells, natural killer cells
Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof. Novel treatments with minimum side effects are one of the main aims of the ongoing cancer research.